CDC36 Antibody

What is CD36 and why is it an important research target?

CD36 is a membrane receptor that participates in the cellular uptake of fatty acids and lipid metabolism. This multifunctional cell surface receptor plays significant roles in various physiological processes including lipid metabolism, innate immunity, and inflammatory responses. CD36 overexpression has been linked to the progression of multiple pathologies, including atherosclerosis and cancer, making it a valuable target for therapeutic interventions . Research on CD36 is particularly important for understanding mechanisms underlying cardiovascular diseases, metabolic disorders, and certain cancer types, as well as developing potential treatments for these conditions.

What types of CD36 antibodies are commonly used in research?

Researchers typically employ several types of CD36 antibodies depending on their experimental needs. Polyclonal antibodies, such as the CD36 Polyclonal Antibody (CAB14714), are produced in rabbits and demonstrate high specificity for human, mouse, and rat samples . These antibodies can be used in Western blot (WB) and immunofluorescence (IF) applications with recommended dilutions ranging from 1:500 to 1:2000 for WB and 1:50 to 1:200 for IF . More specialized antibodies include single-chain variable fragments (scFvs) like the recently discovered D11, which effectively blocks CD36 and shows therapeutic potential in disease models . The selection of the appropriate antibody should be based on the specific research application, target species, and detection method.

How should CD36 antibodies be stored and handled for optimal performance?

Proper storage and handling of CD36 antibodies are crucial for maintaining their functionality and specificity. For optimal preservation, antibodies such as the CD36 Polyclonal Antibody should be stored at -20°C, with care taken to avoid repeated freeze/thaw cycles that can degrade antibody quality . Typically, these antibodies are supplied in a buffer solution consisting of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . When working with the antibody, it's advisable to aliquot the stock solution into smaller volumes to minimize freeze/thaw cycles. Additionally, researchers should adhere to recommended dilution factors for specific applications (such as WB 1:500-1:2000 and IF 1:50-1:200) to ensure optimal results while conserving antibody material .

How can researchers effectively use anti-CD36 in red blood cell antibody screening?

When employing anti-CD36 in red blood cell (RBC) antibody screening, researchers should be aware of its potential interference with screening results. Based on recent findings presented at AABB23, anti-CD36 has been confirmed to interfere with RBC antibody screening, an issue previously only suspected . To address this challenge, researchers can implement rCD36p testing when anti-CD36 interference is suspected in immunohematology reference laboratory settings. This testing approach serves dual purposes: it confirms antibody specificity and facilitates detection of potential underlying RBC alloantibodies with common specificity .

The protocol is particularly important for pregnant individuals, as anti-CD36 has been associated with severe fetal/neonatal thrombocytopenia . When implementing this methodology, researchers should carefully validate their assay using appropriate positive and negative controls, and consider performing parallel tests with and without rCD36p to clearly identify interference patterns. Documentation of patient history, especially regarding pregnancy or transfusion, is also crucial for accurate interpretation of results.

What are the key considerations when evaluating CD36 antibody specificity and cross-reactivity?

Evaluating CD36 antibody specificity and cross-reactivity requires rigorous validation procedures to ensure reliable research outcomes. Researchers should first verify species reactivity, as antibodies like CAB14714 demonstrate specificity for human, mouse, and rat samples . Cross-reactivity testing against related proteins or isoforms is essential to confirm target specificity. This can be accomplished through comparative analysis using positive control samples (such as THP-1, Jurkat, U-937, HeLa, 293T cells, or mouse kidney tissue) known to express CD36 .

For detailed specificity assessment, researchers can employ competitive binding assays using recombinant CD36 proteins or peptides corresponding to the target epitope. For instance, antibodies like CAB14714 are generated against a recombinant fusion protein containing a sequence corresponding to amino acids 301-400 of human CD36 (NP_001120916.1) . Pre-absorption with this specific sequence can help determine whether observed binding is specific to the intended epitope. Additionally, parallel testing in CD36-knockout or CD36-overexpressing cell models provides definitive evidence of antibody specificity. Finally, validation across multiple detection techniques (WB, IF, flow cytometry) helps confirm that specificity is maintained across different experimental conditions.

How can researchers optimize anti-CD36 scFv for therapeutic applications?

Optimizing anti-CD36 scFv for therapeutic applications involves several critical steps following initial development. Recent research with the D11 scFv provides valuable insights into this process . First, researchers should thoroughly characterize the binding kinetics and affinity of the scFv, typically using surface plasmon resonance or bio-layer interferometry to determine kon and koff rates and the resulting KD value. Competition assays with established anti-CD36 antibodies of known efficacy can help validate target binding, as demonstrated with D11 which competes with commercial anti-CD36 antibodies with proven efficacy in disease models .

Functional validation is crucial and should include assays specific to the therapeutic application. For example, in atherosclerosis applications, researchers should assess the scFv's ability to block oxidized LDL (oxLDL) uptake and prevent foam cell formation in macrophage-like THP-1 cells, as demonstrated with D11 which impaired the acquisition of foam cell phenotype induced by oxLDL . For cancer applications, evaluation of the scFv's impact on lipid accumulation and clonogenicity in cancer cell lines like HepG2 is important .

Optimization may also involve protein engineering to improve stability, half-life, or tissue penetration. This could include humanization (if not already human-derived), PEGylation, or fusion to Fc domains to extend circulation time. Finally, researchers should conduct comprehensive toxicity studies in appropriate cell and animal models to identify potential off-target effects before advancing to clinical applications.

How should researchers address anti-CD36 interference in immunoassays?

When encountering anti-CD36 interference in immunoassays, researchers should implement a structured troubleshooting approach. First, confirm suspected interference by testing plasma reactivity neutralization with recombinant CD36 protein (rCD36p), which has been shown to fully neutralize patients' plasma reactivity in cases of anti-CD36 interference . This verification step is particularly important in obstetrical settings, where 76 out of 99 women in a study cohort showed such interference .

For red blood cell antibody screening, researchers should incorporate rCD36p testing into their protocol when interference is suspected. This approach serves the dual purpose of confirming antibody specificity while enabling detection of potential underlying RBC alloantibodies . To systematically address interference, implement a tiered testing strategy similar to that used for Anti-Drug Antibody (ADA) analysis, progressing from initial screening to confirmatory assays and potentially neutralization tests .

Data interpretation should account for patient history, particularly regarding pregnancy or transfusion, as these factors may correlate with anti-CD36 presence . When analyzing results, consider that complete neutralization by rCD36p strongly indicates anti-CD36 as the source of interference, whereas partial neutralization may suggest additional antibodies requiring further investigation. Documentation of these troubleshooting steps and findings is essential for future reference and potential clinical correlations.

What approaches can researchers use to quantify anti-CD36 antibody effects on lipid metabolism?

Quantifying anti-CD36 antibody effects on lipid metabolism requires multiple complementary methodologies. Researchers should begin with oil red O staining to visualize and quantify lipid droplet accumulation in cells treated with CD36 ligands (such as oxLDL or palmitate) with and without anti-CD36 antibodies . This method provides clear visual evidence of the antibody's impact on lipid uptake and storage. For precise quantification, researchers can extract the oil red O dye with isopropanol and measure absorbance spectrophotometrically.

Flow cytometry using fluorescently labeled lipids (such as BODIPY-labeled fatty acids) offers a more sensitive approach for quantifying lipid uptake at the single-cell level. This technique allows researchers to assess the antibody's blocking efficiency by measuring the reduction in fluorescence intensity in anti-CD36-treated cells compared to controls .

RT-qPCR analysis of lipid metabolism genes provides mechanistic insights into how anti-CD36 antibodies affect cellular metabolism. Key genes to monitor include those involved in fatty acid transport, lipid storage, and lipid metabolism, which have been shown to be dysregulated in response to CD36 ligands and modulated by anti-CD36 treatment . For example, researchers working with D11 scFv demonstrated its ability to decrease lipid droplet content and the expression of lipid metabolism genes in macrophage-like THP-1 cells treated with oxLDL .

For comprehensive assessment, these methodologies should be combined with functional assays relevant to the specific research context, such as foam cell formation assays for atherosclerosis research or tumorsphere assays for cancer studies, as employed in the D11 scFv characterization .

How can researchers accurately interpret anti-CD36 antibody data in the context of cancer research?

Interpreting anti-CD36 antibody data in cancer research requires careful consideration of multiple factors. Researchers should first establish baseline CD36 expression levels across their cancer cell lines of interest using quantitative methods such as flow cytometry or western blotting with validated anti-CD36 antibodies . This baseline characterization is essential as CD36 expression varies significantly between cancer types and can correlate with disease progression or prognosis.

When evaluating anti-CD36 therapeutic approaches, researchers should analyze multiple cancer-related phenotypes. For hepatocellular carcinoma models, key assessments include lipid accumulation (using oil red staining), clonogenicity (through tumorsphere assays), and expression of cancer stem cell markers via RT-qPCR . The D11 anti-CD36 scFv, for example, demonstrated efficacy in reducing both lipid accumulation and clonogenicity in HepG2 cells stimulated by palmitate, suggesting potential therapeutic applications .

For data interpretation, researchers should correlate anti-CD36 effects with known CD36-mediated cancer mechanisms, such as fatty acid uptake supporting cancer cell metabolism, cancer stem cell maintenance, or metastatic potential. Control experiments should include isotype-matched antibodies and CD36-knockout or knockdown models to confirm that observed effects are specifically due to CD36 blockade rather than non-specific antibody interactions.

How can anti-CD36 antibodies be utilized in investigating the relationship between lipid metabolism and inflammation?

Anti-CD36 antibodies offer valuable tools for dissecting the complex relationship between lipid metabolism and inflammation in various disease contexts. Researchers can employ these antibodies in dual-staining immunofluorescence protocols to simultaneously visualize CD36-expressing cells (such as macrophages) and inflammatory markers (such as TNF-α or IL-1β), providing spatial information about their relationship in tissue samples . For mechanistic studies, researchers can use blocking anti-CD36 antibodies or scFvs like D11 to inhibit CD36-mediated lipid uptake in macrophages, then measure changes in inflammatory cytokine production using ELISA or multiplex cytokine assays .

Flow cytometry protocols incorporating anti-CD36 antibodies allow researchers to identify and isolate specific cell populations with high CD36 expression from complex tissues, enabling subsequent analysis of their inflammatory profiles. In the context of atherosclerosis research, anti-CD36 antibodies can be used to monitor the formation and inflammatory characteristics of foam cells, as CD36-mediated uptake of oxidized LDL is a critical step in this process .

Time-course experiments combining anti-CD36 treatment with lipidomic and transcriptomic analyses provide comprehensive insights into how CD36 blockade affects both lipid metabolism and inflammatory pathways over time. These multi-omics approaches can reveal previously unrecognized connections between specific lipid species and inflammatory mediators. For clinical relevance, researchers should correlate their in vitro findings with analyses of patient samples, comparing CD36 expression levels with inflammatory markers in diseases such as atherosclerosis, diabetes, or specific cancers .

What role do anti-CD36 antibodies play in studying thrombocytopenia associated with pregnancy?

Anti-CD36 antibodies serve as crucial investigative tools for understanding the mechanisms underlying thrombocytopenia in pregnancy. Research has established that anti-CD36 is associated with severe fetal/neonatal thrombocytopenia, highlighting the importance of detecting these antibodies in obstetrical settings . In a study of 105 patients with suspected anti-CD36, 76 of the 99 women were in obstetrical settings, underlining the particular relevance of this antibody in pregnancy-related complications .

To investigate this relationship, researchers can employ a sequential testing strategy beginning with screening assays to detect anti-CD36 in maternal plasma, followed by confirmatory tests with rCD36p to verify antibody specificity . Quantitative analysis of antibody titers may provide insights into the correlation between antibody levels and severity of thrombocytopenia. Mechanistic studies should examine how anti-CD36 interacts with platelets and megakaryocytes, which express CD36 on their surface.

For clinical correlations, researchers can collect longitudinal samples throughout pregnancy to track anti-CD36 levels in relation to platelet counts in both mother and fetus/neonate. Case-control studies comparing pregnancies with and without thrombocytopenia can help establish the predictive value of anti-CD36 testing. Additionally, in vitro studies using cord blood samples can assess the direct effects of maternal anti-CD36 on neonatal platelets, potentially revealing mechanisms for targeted interventions.

The ultimate goal of this research should be to develop screening protocols for identifying at-risk pregnancies and establishing preventive or therapeutic strategies to mitigate fetal/neonatal thrombocytopenia associated with anti-CD36 antibodies.

How can researchers evaluate the potential of anti-CD36 antibodies in atherosclerosis and cardiovascular disease treatments?

Evaluating anti-CD36 antibodies for atherosclerosis and cardiovascular disease (CVD) treatments requires a comprehensive research strategy spanning from in vitro models to clinical correlations. Researchers should begin with macrophage foam cell assays, where anti-CD36 antibodies like the D11 scFv have demonstrated efficacy in preventing oxLDL uptake and subsequent foam cell formation . This initial screening can be quantified through oil red O staining for lipid accumulation and RT-qPCR analysis of lipid metabolism and inflammatory gene expression .

Advanced in vitro models include three-dimensional arterial wall constructs containing endothelial cells, smooth muscle cells, and monocytes/macrophages, which better recapitulate the complexity of atherosclerotic plaque development. In these models, researchers can evaluate how anti-CD36 treatment affects multiple processes including monocyte adhesion, infiltration, foam cell formation, and plaque stability markers.

For in vivo assessment, researchers should employ established atherosclerosis models such as ApoE-/- or LDLR-/- mice fed a high-fat diet. Key endpoints include plaque size and composition (lipid content, macrophage infiltration, necrotic core size, fibrous cap thickness) following treatment with anti-CD36 antibodies. Non-invasive imaging techniques such as ultrasound or MRI can provide longitudinal assessment of plaque progression.

Pharmacokinetic/pharmacodynamic (PK/PD) studies are essential to establish dosing regimens and determine the relationship between antibody concentration and biomarkers of CD36 activity . This includes analyzing how anti-CD36 antibodies affect drug distribution and efficacy, as illustrated by the differential effects of ADAs on drug concentration-time curves (Figure 4 in ). Finally, translational research correlating CD36 expression in human atherosclerotic plaques with disease progression provides valuable insights into patient populations most likely to benefit from anti-CD36 therapeutic strategies.

What advancements are expected in CD36 antibody development for diagnostic applications?

The future of CD36 antibody development for diagnostics appears promising with several key advancements on the horizon. One significant development is the potential establishment of CD36 as a novel erythroid blood group system, which has been suggested based on recent research findings . This classification would standardize testing protocols and enhance diagnostic accuracy across laboratories. Researchers are also likely to develop more specific high-throughput screening assays using recombinant CD36 protein (rCD36p) to efficiently detect anti-CD36 in patient samples, particularly important in immunohematology reference laboratories .

In pregnancy-related diagnostics, we can anticipate the development of standardized prenatal screening protocols for anti-CD36, given its association with severe fetal/neonatal thrombocytopenia . Such screening would enable early identification of at-risk pregnancies and implementation of preventive measures. For cardiovascular and metabolic disease diagnostics, next-generation antibodies with enhanced specificity for different CD36 conformational states may emerge, potentially distinguishing between CD36 bound to different ligands (oxLDL versus fatty acids).

Multiplex diagnostic platforms incorporating anti-CD36 antibodies alongside other biomarkers of inflammation and metabolic dysfunction will likely be developed, providing more comprehensive patient profiling. Finally, advances in imaging applications may include the development of anti-CD36 antibodies labeled with novel contrast agents for non-invasive visualization of CD36-expressing tissues in conditions such as atherosclerosis, potentially enabling earlier detection and more precise monitoring of disease progression.

How might anti-CD36 antibody research contribute to understanding metabolic syndrome and diabetes?

Anti-CD36 antibody research is poised to significantly advance our understanding of metabolic syndrome and diabetes through several innovative approaches. By employing tissue-specific anti-CD36 antibodies, researchers can systematically map CD36 expression and activity across metabolic tissues (adipose, muscle, liver, pancreas) in normal versus diabetic conditions, revealing tissue-specific roles in disease pathogenesis. Studies utilizing blocking anti-CD36 antibodies like D11 scFv can help determine if CD36 inhibition in specific tissues ameliorates insulin resistance by preventing lipotoxicity, which occurs when excessive fatty acid uptake mediated by CD36 disrupts normal cellular metabolism .

In pancreatic β-cell research, anti-CD36 antibodies enable investigation of how CD36-mediated lipid uptake affects insulin secretion and β-cell survival. This research direction is particularly relevant as lipotoxicity is implicated in β-cell dysfunction in type 2 diabetes. For adipose tissue studies, researchers can use anti-CD36 antibodies to explore how alterations in CD36 expression correlate with adipose tissue inflammation and insulin sensitivity, particularly in the context of obesity.

The relationship between CD36 and adipokines (hormones secreted by adipose tissue) represents another promising research avenue, with anti-CD36 antibodies helping to elucidate potential regulatory relationships. Longitudinal clinical studies correlating anti-CD36 antibody biomarkers with progression from pre-diabetes to overt diabetes could yield valuable predictive markers and therapeutic targets.

Finally, intervention studies in animal models of metabolic syndrome using anti-CD36 therapeutic antibodies will help determine if CD36 blockade can reverse established metabolic dysfunction or prevent its development, potentially paving the way for novel therapeutic approaches for these increasingly prevalent conditions.

What are the ethical and regulatory considerations for developing CD36 antibody-based therapeutics?

Developing CD36 antibody-based therapeutics presents distinct ethical and regulatory challenges that researchers must navigate. Safety concerns are paramount, given CD36's expression across multiple cell types and tissues including platelets, monocytes/macrophages, adipocytes, and endothelial cells . Comprehensive toxicity studies must assess off-target effects and unintended consequences of CD36 blockade in non-target tissues. Particular attention should be paid to potential hematological effects, including impacts on platelet function and risk of bleeding, especially given the association of anti-CD36 with thrombocytopenia in pregnancy settings .

Patient selection and stratification represent another critical consideration. Researchers must develop clear inclusion/exclusion criteria for clinical trials based on CD36 expression levels or related biomarkers to identify patients most likely to benefit from anti-CD36 therapies. This personalized medicine approach raises ethical questions about access and availability of companion diagnostics.

Regulatory pathways for CD36 antibody therapeutics will likely require demonstration of both safety and efficacy in well-defined patient populations through carefully designed clinical trials. These trials should incorporate pharmacokinetic/pharmacodynamic (PK/PD) modeling to understand the relationship between anti-CD36 antibody levels and target engagement biomarkers . Immunogenicity monitoring will be essential, as anti-drug antibodies could potentially neutralize therapeutic anti-CD36 antibodies or cause adverse reactions .

Long-term monitoring protocols must be established to track potential delayed adverse effects, particularly in metabolic and cardiovascular systems where CD36 plays important physiological roles. Finally, researchers must consider intellectual property landscapes and regulatory requirements across different jurisdictions, as these can significantly impact development timelines and accessibility of resulting therapeutics.